Form 4: Ultragenyx Director Sanders Sells 584 Shares of Common Stock
SEC Form 4 Filing
Director Corazon (Corsee) D. Sanders sold 584 shares of Ultragenyx Pharmaceutical Inc. (RARE) common stock at a price of $40.98 on July 2, 2024.
Summary
- On July 2, 2024, Corazon (Corsee) D. Sanders, a director of Ultragenyx Pharmaceutical Inc., sold 584 shares of the company's common stock.
- The sale price was $40.98 per share.
- Following the transaction, Sanders directly owns 12,009 shares of Ultragenyx common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing reporting a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Industry Context
This Form 4 filing is a routine disclosure of a transaction by a company insider. It provides transparency into the trading activities of individuals with access to non-public information. It is important to consider this transaction in the context of the overall market conditions and the company's performance.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, but the impact is likely minimal given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| 07/02/2024 | Date of transaction: Sale of 584 shares of common stock. |
| 07/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.